Roche announced a large-scale investment to build an AI-driven discovery and development engine and signed a partnering agreement with Nvidia to secure the computing backbone for it. The Swiss drugmaker said the initiative will centralize model development, drug design and diagnostics workflows on GPU-heavy infrastructure and expand internal AI capabilities. Industry sources and company statements place the move alongside similar commitments from Eli Lilly and underline an intensifying arms race for compute and data to accelerate hit finding, candidate optimization and biomarker discovery. Roche framed the program as a cross‑company platform to shorten lead times for drug and diagnostic programs and to scale in‑house AI models with commercial-grade validation.